slow prototypes; fast units soon.
Catch the cancer at cell level
The mammofield technology can detect veryveryvery
small bioelectric fields in a non-contact,
non-invasive and non-radiative manner.
Dr. Mchael Levin`s research on cell bioelectric field signatures
at Tufts wherein he speaks about in situ cancer cell bioelectric signatures; mammofield is extra-situ and is non-contact detection of cell biolectric field signatures at a distance:
complementary to mammograms
Complementary to mammograms
PROJECTED INCOME STATEMENT
($ in Millions)
Year 1 Year 2 Year 3 Year 4 Year 5
______ ______ ______ ______ ______
Revenues 9.3 28.3 39.2 54.5 75.7
Cost of Revenue 2.7 9.3 13.5 19.1 26.5
------ ------ ------ ------ ------
Gross Margin 6.6 19.0 25.8 35.5 49.2
William Olivadoti’s cancer research advisors concur that the mammofield® technology offers the possibility to be a reliable harbinger of cell-tumor screening as a complement to x-ray mammograms. The comparatively low-cost mammofield® detection system is non-contact, non-radiative, and non-invasive, being in a comfort zone for all patients. The mammary map produced by mammofield® will be both accurate and to cell level, allowing pinpoint accuracy, thus not allowing subjective conclusions to be drawn from observed data, a deficiency in x-ray mammography. Early cell tumor development detection is the asset of mammofield®, compared with x-ray screening’s sometimes tumor-decade-life before-detection period.
MARKETS: USA is a $3 billion mammography market. William Olivadoti’s mammofield® technology opens vast opportunities to facilitate initial-growth cell detection of breast tumors. mammofield® can increase the survival odds of women thru cell-level tumor identification. The market will welcome mammofield®’s new non-invasive, non-radiative and cell-level accurate tumor detection which will capture a large share of the preventive healthcare market. The targets will be researchers, clinics and hospitals. Trials may take place in other countries exchange for licensing rights to facilitate U.S. FDA acceptance.
Hospitals $60 million &am
Barriers to Entry
TransScan has a non-invasive, non-radiation T-Scan product utilizing a multi-electrode sensor array pressed against the breast for detection of breast cancer based on TransSpectral Impedance Scanning . This is uncomfortable but has resulted in increased detection rates. There are currently four digital mammography manufacturers: General Electric, Fisher, LoRad, and Fuji. Standard x--ray mfg’s are: Advanced Instrument Development , Faxitron X-Ray Corporation, Fischer Imaging Corporation, GE Medical Systems, Instrumentarium Imaging, Inc., Philips Medical Systems and Toshiba America Medical Systems. Magnetic resonance imaging (MRI), ultrasound and thermal imaging are also being used. mammofield® provides for a greater cancer screening research methodology at lower cost, fewest parts, better reliability and more accurate capability than those or any other mammogram technology. A patent has been granted for this technology.
$0 bucks thus far; have a pension fund @ $1.5 M and a VC , both ready to co-invest at end of clinical trails;